Lung Cancer

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.

Roy S. Herbst, MD, PhD, highlights the evolution of EGFR TKIs and the need for treatments improving DFS and OS outcomes in EGFR-mutant NSCLC.

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

Heather Wakelee, MD, discusses underlying resistance mechanisms and potential therapies for EGFR+ NSCLC following osimertinib.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

The FDA has granted breakthrough therapy designation to elironrasib for KRAS G12C–mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

The FDA granted fast track designation to DB-1310 for patients with pretreated, advanced non–small cell lung cancer harboring select EGFR mutations.

Evan S. Wu, Md, PhD, concludes a three-part series highlighting the translatability of Chinese clinical data into US regulatory pathways.

Panelists discuss how subcutaneous (SQ) nivolumab administration offers patient convenience and potential logistical advantages, particularly in the maintenance setting, though they acknowledge limited current adoption and need for more biological data on efficacy differences.

Panelists discuss how borderline resectable patients can be made resectable through neoadjuvant chemoimmunotherapy when surgeons have clear, objective goals for what they aim to achieve rather than vague hopes to make surgery “less scary.”